DANVERS, Mass. (November 8, 2006)—Abiomed, Inc. (NASDAQ: ABMD) today announced revenue of $10.9 million for its second fiscal quarter ended September 30, 2006.  Revenue for the first six months of fiscal 2007 was $23.9 million, up approximately 23% compared to revenue of $19.4 million in the first six months of fiscal 2006. 

Comparing the second fiscal quarter of 2007 revenue of $10.9 million to the second fiscal quarter of 2006 revenue of $10.9 million, AB5000 grew 31%, and BVS decreased approximately 37%.  While not a significant contribution to total revenue for the second fiscal quarter of 2007, revenues from Impella increased 75% compared to the same period of fiscal 2006.

Recent operating highlights and financial results for the second fiscal quarter of 2007 as compared to the second fiscal quarter of 2006 included:

• The Company’s AbioCor® Implantable Replacement Heart received approval from the U.S. Food and Drug Administration under a Humanitarian Device Exemption (HDE). 

• Revenue from console sales (AB5000 and Impella) grew 85%.
• The highest number of patients placed on AB5000 Circulatory Support worldwide.
• Commencement of the Impella 2.5 pilot study in the United States.
• Gross margin for the second fiscal quarter of 2007 was 73%.

• The second fiscal quarter of 2007 reported net loss was $8.7 million, or $.33 per share.  The net loss for the second fiscal quarter of 2007 included stock option expense of approximately $1.6 million, or $.06 per share. 

 “We are focused on executing our strategic goals and made progress this quarter on expanding our product portfolio with regulatory approvals and growing our global distribution,” said Michael R. Minogue, Chairman, CEO and President of Abiomed.

Financial information for the second quarter of fiscal 2007 is attached to this press release.    

CONFERENCE CALL AND WEBCAST

The Company will host a conference call at 4:30 p.m. ET on November 8, 2006. Michael R. Minogue, Chairman, Chief Executive Officer and President, and Daniel J. Sutherby, Chief Financial Officer, will host the conference call.

To listen to the call live, please tune into the webcast via www.abiomed.com/investors or dial 800-659-2056; the international number is 617-614-2714. The conference call passcode is 99611049.  A replay of this conference call will be available beginning at 6:30 p.m ET on November 8, 2006, through 6:30 p.m. ET on November 15, 2006. The replay phone number is 888-286-8010; the international number is 617-801-6888. The replay access code is 60928364.    

ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. Abiomed currently manufactures and sells the AB5000™ Circulatory Support System and the BVS® 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. In Europe, Abiomed offers the minimally invasive Impella® Circulatory Support Systems under CE Mark approval. The Impella® 5.0 and 2.5 are investigational devices limited by Federal Law solely to investigational use in the United States. Other Impella devices are not yet available for sale in the United States. The Company's AbioCor® Implantable Replacement Heart is now available under a Humanitarian Device Exemption granted by the United States Food and Drug Administration. For additional information please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements regarding development of Abiomed’s existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.

Contacts:
Liza Heapes
ABIOMED, INC.
Media Relations
(978) 646-1668
mediarelations@abiomed.com

Daniel Sutherby
ABIOMED, INC.
Chief Financial Officer
(978) 646-1812
ir@abiomed.com

###

ABIOMED, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(in thousands, except share data)

ABIOMED, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands, except per share and share data)